TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$34.19
-0.70%
$39.8B
No data for this timeframe.
Vol
Market Cap$39.8B
Cap SizeLarge Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders10 funds
Inst. Value$2.7B
Inst. Activity3 buys / 2 sells
Insider Activity0B / 15S
Insider Net $-$18.1M
Reddit Sentiment50° Neutral
SEC Reports8
Press Releases4
Recent Activity
Jun 5, 2026
Press
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's d
Impact 4/10
Jun 5, 2026
fda
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
<p>PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals,
Jun 3, 2026
Insider
Shields Matthew sold 16,195 shares
EVP, Global Operations @ $0.00 ($0.00)
Jun 3, 2026
Insider
Shields Matthew sold 16,195 shares
EVP, Global Operations @ $32.87 ($532.3K)
Jun 3, 2026
Insider
Shields Matthew sold 16,195 shares
EVP, Global Operations @ $0.00 ($0.00)
May 18, 2026
SEC
TEVA insiders sold $5.66M in stock on May 14, 2026, led by CFO Eliyahu Sharon Kalif ($5.46M). The sales occurred at ~$35
CLUSTER — Impact 2/10
May 13, 2026
Event
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.
Class II: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.
Apr 29, 2026
SEC
Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98B, beating $3.79B by
PRESS-RELEASE — Impact 6/10
Price Targets
$41.27
+20.7% upside
Strong Buy
Current $34.19
Low $33.00
Median $40.00
High $50.00
11 analysts
$33.00
$50.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 6, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 30, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| Apr 30, 2026 | UBS | MAINTAIN | Buy → Buy |
| Apr 30, 2026 | Piper Sandler | REITERATE | Overweight → Overweight |
| Apr 30, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.55 ▼ -2.9% | $0.13 — $0.65 | -17% YoY | 10 |
| Next Q | $0.42 ▼ -19.7% | $0.15 — $0.77 | -46% YoY | 10 |
| Current FY | $2.37 ▼ -1.3% | $1.96 — $2.94 | -19% YoY | 13 |
| Next FY | $3.10 | $2.92 — $3.21 | 31% YoY | 13 |
Latest Reports
NEUTRAL
Press
4/10
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's d
Jun 5, 2026
NEUTRAL
CLUSTER
2/10
TEVA insiders sold $5.66M in stock on May 14, 2026, led by CFO Eliyahu Sharon Kalif ($5.46M). The sales occurred at ~$35
May 18, 2026
MIXED
PRESS-RELEASE
6/10
Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98B, beating $3.79B by
Apr 29, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NORGES BANK | $1.1B | NEW |
| FMR LLC | $905.6M | TRIM |
| MORGAN STANLEY | $263.6M | ADD |
| BANK OF AMERICA CORP | $200.1M | — |
| SOUND SHORE MANAGEMENT INC | $134.5M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Shields Matthew | M | $0.00 |
| Jun 3, 2026 | Shields Matthew | SELL | $532.3K |
| Jun 3, 2026 | Shields Matthew | M | $0.00 |
| May 28, 2026 | Zaks Tal | A | $0.00 |
| May 28, 2026 | Satchi-Fainaro Ronit | A | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
10 institutional holders with $2.7B total value (93,196,527 shares) as of 2025-Q4. Top holders: NORGES, FMR, MORGAN. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NORGES BANK | 35,182,949 | $1.1B | 40.3% | NEW |
| 2 | FMR LLC | 29,014,982 | $905.6M | 33.2% | TRIM -57.6% |
| 3 | MORGAN STANLEY | 8,444,801 | $263.6M | 9.7% | ADD +30.4% |
| 4 | BANK OF AMERICA CORP /DE/ | 6,412,808 | $200.1M | 7.3% | — |
| 5 | SOUND SHORE MANAGEMENT INC /CT/ | 4,309,906 | $134.5M | 4.9% | — |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,130,663 | $66.5M | 2.4% | ADD +28.8% |
| 7 | VANGUARD GROUP INC | 911,674 | $28.5M | 1.0% | — |
| 8 | WELLS FARGO & COMPANY/MN | 647,853 | $20.2M | 0.7% | — |
| 9 | TWO SIGMA INVESTMENTS, LP | 266,021 | $8.3M | 0.3% | DOUBLED +121.0% |
| 10 | Duquesne Family Office LLC | 5,874,870 | $183.4K | 0.0% | TRIM -64.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 35,182,949 | — | $1.1B | 2025-Q4 |
| MORGAN STANLEY | ADD | 6,475,018 | 8,444,801 | +30.4% | $263.6M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 120,397 | 266,021 | +121.0% | $8.3M | 2025-Q4 |
| Duquesne Family Office LLC | TRIM | 16,593,935 | 5,874,870 | -64.6% | $183.4K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 1,002,545 | 0 | -100.0% | $0.00 | 2025-Q4 |
| FMR LLC | TRIM | 58,135,616 | 24,641,362 | -57.6% | $497.8M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 3,156,982 | 1,002,545 | -68.2% | $20.3M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 319,894 | 120,397 | -62.4% | $2.4M | 2025-Q3 |
| NORGES BANK | EXIT | 1,864,684 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | TRIM | 82,742,016 | 58,135,616 | -29.7% | $974.4M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 10,997,926 | 6,613,553 | -39.9% | $110.8M | 2025-Q2 |
| UBS Group AG | TRIM | 7,355,071 | 5,395,188 | -26.6% | $90.4M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 5,301,245 | 3,156,982 | -40.4% | $52.9M | 2025-Q2 |
| NORGES BANK | NEW | — | 1,864,684 | — | $31.3M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 136,797 | 319,894 | +133.8% | $5.4M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 14,911,119 | 10,997,926 | -26.2% | $169.0M | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 10,625,222 | 7,423,991 | -30.1% | $114.1M | 2025-Q1 |
| UBS Group AG | DOUBLED | 2,599,623 | 7,355,071 | +182.9% | $113.0M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,028,924 | 1,324,936 | +28.8% | $20.4M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 686,455 | 136,797 | -80.1% | $2.1M | 2025-Q1 |
| Duquesne Family Office LLC | ADD | 8,997,400 | 14,879,750 | +65.4% | $228.7K | 2025-Q1 |
| NORGES BANK | EXIT | 1,749,070 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 6,302,762 | 10,625,222 | +68.6% | $234.2M | 2024-Q4 |
| UBS Group AG | ADD | 1,710,094 | 2,599,623 | +52.0% | $57.3M | 2024-Q4 |
| Duquesne Family Office LLC | DOUBLED | 1,427,950 | 8,997,400 | +530.1% | $198.3K | 2024-Q4 |
19 unique insiders with 15 transactions. Net insider value: -$18.1M ($0.00 bought, $18.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | M | 16,195 | $0.00 | $0.00 |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | SELL | 16,195 | $32.87 | $532.3K |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | M | 16,195 | $0.00 | $0.00 |
| May 28, 2026 | Zaks Tal Zvi | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | Satchi-Fainaro Ronit | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | Nisen Perry | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | Elstein Amir | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | Lichtenstein Chen | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | BARER SOL J | Director | A | 10,863 | $0.00 | $0.00 |
| May 28, 2026 | Crane Rosemary A | Director | A | 7,242 | $0.00 | $0.00 |
| May 28, 2026 | MIGNONE ROBERTO | Director | A | 7,242 | $0.00 | $0.00 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | M | 11,841 | $0.00 | $0.00 |
| May 14, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | SELL | 153,251 | $35.61 | $5.5M |
| May 14, 2026 | Lippman Evan | EVP, Business Development | M | 11,841 | $0.00 | $0.00 |
| May 14, 2026 | Lippman Evan | EVP, Business Development | SELL | 5,746 | $35.58 | $204.5K |
| May 6, 2026 | Weiss Amir | Chief Accounting Officer | SELL | 10,679 | $36.00 | $384.4K |
| May 5, 2026 | Daniell Richard | EVP, Europe Commercial | SELL | 30,000 | $35.40 | $1.1M |
| May 1, 2026 | Sabag Mark | See "Remarks" | SELL | 144,180 | $34.99 | $5.0M |
| Apr 30, 2026 | Fox Christine | EVP, U.S. Commercial | SELL | 21,258 | $35.31 | $750.6K |
| Mar 17, 2026 | Sabag Mark | See "Remarks" | SELL | 62,102 | $30.14 | $1.9M |
| Mar 5, 2026 | Sabag Mark | See "Remarks" | M | 15,723 | $0.00 | $0.00 |
| Mar 5, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | M | 19,916 | $0.00 | $0.00 |
| Mar 5, 2026 | Savage Brian | Interim Chief Legal Officer | M | 3,580 | $0.00 | $0.00 |
| Mar 5, 2026 | Savage Brian | Interim Chief Legal Officer | M | 3,580 | $0.00 | $0.00 |
| Mar 5, 2026 | Daniell Richard | EVP, Europe Commercial | M | 17,295 | $0.00 | $0.00 |
| Mar 5, 2026 | Jover Placid | See "Remarks" | SELL | 14,150 | $31.67 | $448.1K |
| Mar 5, 2026 | Francis Richard D | President and CEO | M | 42,452 | $0.00 | $0.00 |
| Mar 5, 2026 | Francis Richard D | President and CEO | SELL | 20,025 | $31.67 | $634.2K |
| Mar 5, 2026 | Weiss Amir | Chief Accounting Officer | M | 3,537 | $0.00 | $0.00 |
| Mar 5, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | M | 19,916 | $0.00 | $0.00 |
| Mar 5, 2026 | Sabag Mark | See "Remarks" | M | 15,723 | $0.00 | $0.00 |
| Mar 5, 2026 | Weiss Amir | Chief Accounting Officer | M | 3,537 | $0.00 | $0.00 |
| Mar 5, 2026 | Francis Richard D | President and CEO | M | 42,452 | $0.00 | $0.00 |
| Mar 5, 2026 | Fox Christine | EVP, U.S. Commercial | SELL | 7,924 | $31.67 | $250.9K |
| Mar 5, 2026 | Fox Christine | EVP, U.S. Commercial | M | 17,819 | $0.00 | $0.00 |
| Mar 5, 2026 | Fox Christine | EVP, U.S. Commercial | M | 17,819 | $0.00 | $0.00 |
| Mar 5, 2026 | Hughes Eric A | See "Remarks" | SELL | 9,533 | $31.67 | $301.9K |
| Mar 5, 2026 | Hughes Eric A | See "Remarks" | M | 19,654 | $0.00 | $0.00 |
| Mar 5, 2026 | Hughes Eric A | See "Remarks" | M | 19,654 | $0.00 | $0.00 |
| Mar 5, 2026 | Daniell Richard | EVP, Europe Commercial | SELL | 17,295 | $31.67 | $547.7K |
| Mar 5, 2026 | Daniell Richard | EVP, Europe Commercial | M | 17,295 | $0.00 | $0.00 |
| Mar 5, 2026 | Jover Placid | See "Remarks" | M | 14,150 | $0.00 | $0.00 |
| Mar 5, 2026 | Jover Placid | See "Remarks" | M | 14,150 | $0.00 | $0.00 |
| Mar 5, 2026 | Savage Brian | Interim Chief Legal Officer | SELL | 1,127 | $31.67 | $35.7K |
| Mar 5, 2026 | Shields Matthew | EVP, Global Operations | M | 17,295 | $0.00 | $0.00 |
| Mar 5, 2026 | Shields Matthew | EVP, Global Operations | SELL | 17,295 | $31.67 | $547.7K |
| Mar 5, 2026 | Shields Matthew | EVP, Global Operations | M | 17,295 | $0.00 | $0.00 |
| Mar 4, 2026 | Sabag Mark | See "Remarks" | M | 33,512 | $0.00 | $0.00 |
| Mar 4, 2026 | Sabag Mark | See "Remarks" | A | 30,385 | $0.00 | $0.00 |
| Mar 4, 2026 | Daniell Richard | EVP, Europe Commercial | M | 33,512 | $0.00 | $0.00 |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 4 neutral. Avg impact: 4.9/10.
NEUTRAL
CLUSTER
2/10
TEVA insiders sold $5.66M in stock on May 14, 2026, led by CFO Eliyahu Sharon Kalif ($5.46M). The sa
May 18, 2026
MIXED
PRESS-RELEASE
6/10
Teva reported Q1 2026 non-GAAP EPS of $0.53, beating consensus of $0.46 by 15%, and revenue of $3.98
Apr 29, 2026
BULLISH
COURT-RULING
8/10
The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment invalidating Tev
Apr 16, 2026
BEARISH
CLUSTER
6/10
Seven executives at Teva Pharmaceutical exercised stock derivatives and several conducted open-marke
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
Seven executives at Teva Pharmaceutical exercised stock options and sold shares in the open market o
Mar 9, 2026
NEUTRAL
CLUSTER
3/10
Teva executives executed derivative exercises and received share grants totaling $0 in cash value, w
Mar 9, 2026
NEUTRAL
CLUSTER
4/10
Multiple Teva executives, including the CEO, CFO, and other C-suite officers, exercised stock option
Mar 9, 2026
MIXED
INST-CLUSTER
6/10
In Q4 2025, a mixed institutional cluster emerged in Teva Pharmaceutical, with three major instituti
Feb 28, 2026
NEUTRAL
4/10
Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatmen
Jun 5, 2026
NEUTRAL
3/10
Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of you
May 18, 2026
BULLISH
6/10
Teva acquires Emalex Biosciences for $700M upfront plus up to $200M in milestones and royalties, gai
Apr 29, 2026
NEUTRAL
3/10
Teva Pharmaceutical announced the date for its Q1 2026 earnings release on April 29, 2026, and publi
Mar 19, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$41.27 mean target
+20.7% upside
Strong Buy (1.38)
$33.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $34.19 |
| Target Low | $33.00 |
| Target Mean | $41.27 |
| Target Median | $40.00 |
| Target High | $50.00 |
| # Analysts | 11 |
| Recommendation | Strong Buy (1.38) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.55 | $0.13 | $0.65 | -17.2% | -2.9% | 2↑ 6↓ | $4.1B | -2.7% | 10 |
| Next Q 2026-09-30 |
$0.42 | $0.15 | $0.77 | -45.5% | -19.7% | 1↑ 7↓ | $4.2B | -5.2% | 10 |
| Current FY 2026-12-31 |
$2.37 | $1.96 | $2.94 | -19.3% | -1.3% | 3↑ 5↓ | $16.7B | -3.5% | 13 |
| Next FY 2027-12-31 |
$3.10 | $2.92 | $3.21 | 31.1% | +0.1% | 7↑ 3↓ | $17.3B | 3.7% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.546 | |
| 7d ago | $0.559 | -0.013 |
| 30d ago | $0.563 | -0.016 |
| 60d ago | $0.643 | -0.097 |
| 90d ago | $0.659 | -0.113 |
9 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 6, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 30, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 30, 2026 | UBS | MAINTAIN | Buy | Buy |
| Apr 30, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Apr 30, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Apr 9, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | REITERATE | Overweight | Overweight |
| Feb 18, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Jan 30, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jan 29, 2026 | Scotiabank | MAINTAIN | Sector Outperform | Sector Outperform |
| Jan 29, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 6, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| Dec 22, 2025 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Dec 19, 2025 | Goldman Sachs | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Dec 9, 2025 | B of A Securities | MAINTAIN | Buy | Buy |
| Dec 9, 2025 | Barclays | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
🟩🎩EMBC - TEVA , Zydus,Sandoz in 🇨🇦
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
fda
Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea
<p>PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries
Jun 3, 2026
Clinical Trial
Study Evaluating Subjects With Distal Renal Tubular Acidosis
Phase Phase 3 — TERMINATED
Jun 2, 2026
Clinical Trial
Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome
Phase Phase 3 — COMPLETED
Jun 2, 2026
short_volume
Short Volume: TEVA — 58.0% short (2.3M / 4.0M)
Short: 2,336,672 | Exempt: 3,251 | TRF Vol: 4,031,384 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
other
Teva to Present at the Goldman Sachs Global Healthcare Conference
<p>PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announc
Jun 1, 2026
short_volume
Short Volume: TEVA — 55.9% short (1.4M / 2.4M)
Short: 1,356,300 | Exempt: 805 | TRF Vol: 2,428,376 | Short Ratio: 55.9% | Off-exchange volume (dark pool + OTC)
May 29, 2026
Clinical Trial
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Phase Phase 3 — COMPLETED
May 29, 2026
Clinical Trial
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Phase Phase 2 — COMPLETED
May 29, 2026
short_volume
Short Volume: TEVA — 66.8% short (1.3M / 2.0M)
Short: 1,330,915 | Exempt: 10,202 | TRF Vol: 1,993,514 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
May 28, 2026
Clinical Trial
Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice
Phase Phase 2 — COMPLETED
May 27, 2026
short_volume
Short Volume: TEVA — 57.8% short (1.0M / 1.7M)
Short: 964,698 | Exempt: 2,412 | TRF Vol: 1,670,235 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: TEVA — 63.5% short (1.1M / 1.7M)
Short: 1,085,462 | Exempt: 8,170 | TRF Vol: 1,709,017 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 21, 2026
other
The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults
<p>TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industr
May 19, 2026
short_volume
Short Volume: TEVA — 61.9% short (0.6M / 1.0M)
Short: 643,154 | Exempt: 2,800 | TRF Vol: 1,039,439 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
May 18, 2026
other
Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution
<p align="justify">TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that
May 18, 2026
fda
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
<p>PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries
May 18, 2026
short_volume
Short Volume: TEVA — 58.6% short (1.3M / 2.3M)
Short: 1,320,062 | Exempt: 3,398 | TRF Vol: 2,253,411 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: TEVA — 61.0% short (0.9M / 1.4M)
Short: 852,785 | Exempt: 223 | TRF Vol: 1,398,836 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_interest
FTD: TEVA — 100,000 shares ($3.6M) failed to deliver
Settlement: 20260513, Price: $35.81, FTD Value: $3,581,000, TEVA PHARMACEUTICAL LTD INDS A
May 13, 2026
FDA
Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, In Single-Dose kits containing: 8-mL vial of 30 mg strength, a pre-filled syringe containing 2 mL of diluent, one vial adapter, and one sterile 1¿ 19-gauge safety injection needle, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 69300 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054. NDC Kit Carton: 0480-9262-08; Vial Label: 0480-9260-01; Tray Label: 0480-9262-08; Diluent Label: 0480-9263-21.
Class II: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at
May 12, 2026
short_volume
Short Volume: TEVA — 72.0% short (1.2M / 1.6M)
Short: 1,178,345 | Exempt: 5,531 | TRF Vol: 1,637,701 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
May 1, 2026
FDA
AZACITIDINE
Unavailable: Estimated recovery: TBD (Other) [Oncology]
Apr 29, 2026
FDA
Claravis (isotretinoin capsule, USP), 10 mg, Packaged as a) 100-count carton, NDC 0555-1054-56, with 10x10 blister packs NDC 0555-1054-60; b) 30-count carton, NDC 0555-1054-86, with 3X10 blister pack NDC 0555-1054-60; Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454.
Class II: Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
Apr 16, 2026
Enforcement
Teva Pharmaceuticals International Gmbh v. Eli Lilly and Company
Court ruling from Court of Appeals for the Federal Circuit. Docket: 24-1094
Apr 15, 2026
FDA
EPYSQLI
WARNING: SERIOUS MENINGOCOCCAL INFECTIONS Eculizumab products, complement inhibitors, increase the risk of serious infections caused by Neisseria meni